Brought to you by 
Alnylam, Isis license Stanford's IP relating to HCV
18 Mar 2011
Executive Summary
Alnylam Pharmaceuticals (therapeutics based on RNA interference--RNAi) and antisense drug developer Isis Pharmaceuticals licensed co-exclusive rights from Stanford University to IP covering the microRNA (miRNA) gene miR-122 that is implicated in hepatitis C virus replication.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alnylam, Isis license Stanford's IP relating to HCV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice